Rociletinib(CO-1686)
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- China
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- 388082-78-8, rociletinib, co-1686, 1374640-70-6
- Category
- Pharmaceutical Intermediates
Shangdong Shinning Pharm co.ltd
China
- Verified Certificate
-
7
| Product name | Rociletinib(CO-1686) | Certification | - |
|---|---|---|---|
| Category | Pharmaceutical Intermediates | Ingredients | - |
| Keyword | 388082-78-8 , rociletinib , co-1686 , 1374640-70-6 | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | China | Stock | - |
| Supply type | - | HS code | - |
Product Information
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Mr. Jin
- Address
- Taishan Road, Ningyang Economic Development Zone, Tai'an, Shandong
- Product Category
- Pharmaceutical Intermediates
- Year Established
- 2011
- No. of Total Employees
- 101-500
- Company introduction
-
<p>
Shandong Shinning Pharm co.ltd is located in Taishan Road, Ningyang Economic Development Zone, Tai'an, Shandong ,. Shinning Pharm dedicates itself on research, develop and industrialize of intermediates and non-infringed synthetic route, serves global customers with high-class products and technologies, based on the professional develop ability and excellent business philosophy.
With the support of national, provincial and district government, Shandong Shinning has achieved more than 100% annual growth rate since its foundation to a group incorporating 3 wholly-owned subsidiaries:Jinnan Xuande-700m2 – research institute with 50L and 100L reactor, 100L hydrogenation reactor and other instruments, shandong Shinning 3000 m2 – PLANT With 500L, 1000L, 2000L, 5000L reactor and vacuum pump，Taizhou Crene 200 m2 for chemical reagents and kinase inhibitors warehouse .
The company will be a great pharmaceutical corporation with complete industry chain of research, development, production and marketing.
Shandong Shinning invested not less than 30 percent of annual revenue in research and development study, and R&D personnel account for near 70% of total 200 employees.
- Main Product
